pifithrin has been researched along with Cholangiocellular Carcinoma in 1 studies
pifithrin: a tetrahydrobenzothiazol; inhibitor of P53 that protects mice from the side effects of cancer therapy; structure in first source
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pifithrin-alpha was shown to activate aryl hydrocarbon receptor (AhR) signaling and p38 MAPK activation." | 1.33 | Pifithrin-alpha enhances chemosensitivity by a p38 mitogen-activated protein kinase-dependent modulation of the eukaryotic initiation factor 4E in malignant cholangiocytes. ( Henson, R; Lang, M; Meng, F; Patel, T; Wehbe, H, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wehbe, H | 1 |
| Henson, R | 1 |
| Lang, M | 1 |
| Meng, F | 1 |
| Patel, T | 1 |
1 other study available for pifithrin and Cholangiocellular Carcinoma
| Article | Year |
|---|---|
Pifithrin-alpha enhances chemosensitivity by a p38 mitogen-activated protein kinase-dependent modulation of the eukaryotic initiation factor 4E in malignant cholangiocytes.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Benzothiazoles; Bile Duct Neoplasms; Cell Co | 2006 |